Bosentan PAH (WHO-FC II)
Phase 3
- Conditions
- Pulmonary arterial hypertension (PAH)
- Registration Number
- JPRN-jRCT2080221952
- Lead Sponsor
- Actelion Pharmaceuticals Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
* PAH idiopathic
* PAH familial
* PAH secondary to connective tissue or auto-immune diseases
* PAH secondary to atrial septum defect (ASD)<2 cm, ventricular septum defect (VSD) <1 cm or patent ductus arteriosus (PDA)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method